Neumora Therapeutics (NASDAQ:NMRA) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Neumora Therapeutics (NASDAQ:NMRA) announced its quarterly earnings results on Monday. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01), FiscalAI reports.

Neumora Therapeutics Stock Performance

NASDAQ:NMRA opened at $2.33 on Monday. Neumora Therapeutics has a 12-month low of $0.61 and a 12-month high of $3.65. The company has a current ratio of 6.85, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15. The stock’s 50 day simple moving average is $2.74 and its 200-day simple moving average is $2.32. The firm has a market cap of $389.32 million, a P/E ratio of -1.59 and a beta of 2.46.

Insiders Place Their Bets

In related news, insider Paul L. Berns sold 9,819 shares of Neumora Therapeutics stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $3.51, for a total value of $34,464.69. Following the transaction, the insider directly owned 7,395,185 shares in the company, valued at $25,957,099.35. This trade represents a 0.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last 90 days, insiders have sold 23,387 shares of company stock valued at $82,647. Company insiders own 26.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Hsbc Holdings PLC acquired a new position in shares of Neumora Therapeutics during the 4th quarter worth $27,000. Virtu Financial LLC acquired a new position in Neumora Therapeutics during the third quarter worth about $31,000. Fred Alger Management LLC purchased a new stake in shares of Neumora Therapeutics in the fourth quarter valued at about $40,000. Public Employees Retirement System of Ohio purchased a new stake in Neumora Therapeutics in the 3rd quarter valued at approximately $44,000. Finally, Barclays PLC raised its holdings in Neumora Therapeutics by 202.0% in the 4th quarter. Barclays PLC now owns 30,924 shares of the company’s stock valued at $55,000 after acquiring an additional 20,683 shares during the last quarter. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on NMRA shares. Leerink Partners began coverage on Neumora Therapeutics in a research report on Monday, January 12th. They issued an “outperform” rating and a $8.00 target price for the company. Mizuho set a $6.00 price objective on Neumora Therapeutics in a report on Monday, January 5th. William Blair upgraded shares of Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neumora Therapeutics in a research report on Thursday, January 22nd. Finally, Royal Bank Of Canada raised shares of Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and raised their price objective for the stock from $4.00 to $7.00 in a research report on Monday, December 1st. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, Neumora Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $6.71.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.